SCHEMBL4476901

SCHEMBL4476901

COc1cc2nccc(Oc3ccc(NC(=O)NC4CCCC(C)(C)C4)c(Cl)c3)c2cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 10/20 0.67
KDR P35968 8/20 0.67
PDGFRA P16234 6/20 0.67
KIT P10721 5/20 0.67
FLT1 P17948 5/20 0.67
FLT4 P35916 5/20 0.67
FGFR1 P11362 4/20 0.67
RET P07949 4/20 0.67
PDGFRB P09619 3/20 0.67
FGFR2 P21802 3/20 0.67
RIPK2 O43353 2/20 0.67
STK10 O94804 2/20 0.67
ABL1 P00519 2/20 0.67
BCR P11274 2/20 0.67
SLC6A3 Q01959 2/20 0.67
DDR1 Q08345 2/20 0.67
MAP4K2 Q12851 2/20 0.67
PTK6 Q13882 2/20 0.67
DDR2 Q16832 2/20 0.67
AURKB Q96GD4 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475372 0.91 KDR (0.67) FGFR4KDRPDGFRAKITFLT1
SCHEMBL4470899 0.88 PDGFRA (0.79) KDRPDGFRAKITAURKBMET
SCHEMBL4478514 0.87 FGFR4 (0.67) FGFR4KDRPDGFRAKITFLT1
SCHEMBL13936784 0.87 KDR (0.60) FGFR4KDRPDGFRAKITFLT1
SCHEMBL4465646 0.85 PDGFRA (0.61) FGFR4KDRPDGFRAKITFLT1
Hydrochloric Acid SCHEMBL6234370 0.84 PDGFRA (0.61) FGFR4KDRPDGFRAKITFLT1
SCHEMBL1889234 0.83 FGFR4 (0.83) FGFR4KDRPDGFRAKITFLT1
SCHEMBL13613030 0.83 FGFR4 (0.78) FGFR4KDRPDGFRAKITFLT1
SCHEMBL3977338 0.83 FGFR4 (0.80) FGFR4KDRPDGFRAKITFLT1
SCHEMBL12503770 0.82 FGFR4 (0.80) FGFR4KDRPDGFRAKITFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR4 7/4885KDR 211/4885PDGFRA 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.